Accelerate Diagnostics (NASDAQ: AXDX) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
This is a breakdown of recent ratings and recommmendations for Accelerate Diagnostics and Precipio, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accelerate Diagnostics currently has a consensus target price of $33.00, suggesting a potential upside of 48.98%. Given Accelerate Diagnostics’ higher probable upside, analysts plainly believe Accelerate Diagnostics is more favorable than Precipio.
Valuation and Earnings
This table compares Accelerate Diagnostics and Precipio’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Accelerate Diagnostics||$4.18 million||286.04||-$64.02 million||($1.16)||-19.09|
|Precipio||$1.72 million||4.92||-$20.69 million||N/A||N/A|
Precipio has lower revenue, but higher earnings than Accelerate Diagnostics.
Risk & Volatility
Accelerate Diagnostics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Precipio has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Insider and Institutional Ownership
45.3% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 7.4% of Precipio shares are held by institutional investors. 49.3% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 24.7% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Accelerate Diagnostics and Precipio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Accelerate Diagnostics beats Precipio on 9 of the 11 factors compared between the two stocks.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Precipio, Inc. provides platform to eradicate the problem of misdiagnosis within academic institutions. The company also delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.